Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penicillin G plus aminoglycoside versus meropenem for empiric treatment of febrile neutropenia in lymphoma and leukemia
2005-004211-30Phase 4Completed
- Sponsor
- The Norwegian Radium Hospital
- Start
- Sep 2005
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of benzylpenicillin, tobramycin, gentamicin, netilmicin and meropenem in febrile neutropenia (FN) (2 arms), sponsored by The Norwegian Radium Hospital. Primary endpoint: Success at 72 hours of initial empiric antibiotic therapy. Started Sep 2005; status: completed.
02
Drugs
benzylpenicillintobramycingentamicinnetilmicinmeropenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2005-004211-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004211-30.